Table 1 Average PSV (cm/s) before and after treatment as stratified by various subgroups

From: Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study

    Average PSV  
Group Patients Age Before treatment After treatment P value a
A (no vasculop.) PGE1 1–3 times/week (vasculop.) 10 54.6±11.4 42.7±11.1 42.8±11.3 >0.05.
S (no vasculop.) (oral sildenafil) 25 mg at bedtime/night × 1 month 10 55.6±4.6 54.3±12.9 54.9±12.2 >0.05
Av (vasculop.) PGE1 1–3 times/week (vasculop.) 11 56.1±7.5 20.4±5.2 28.3±9.2 <0.05
Sv (vasculop.) (oral sildenafil) 25 mg at bedtime/night × 1 month 12 59.6±6.4 20.5±3.8 25.5±7.2 <0.05
P (vasculop.) (placebo) at bedtime/night for 1 month 12 57.8±6.4 19.6±3.0 21.6±6.3 >0.05
  1. Data were reported as mean±s.d.
  2. aIn vasculogenic impotent men, PSV significantly increased (P<0.05); in some of them, this increase exceeded the normal value of 30 cm/s. The other subgroups, including placebo, remained unchanged.